Últimas noticias sobre XChange Tec (NASDAQ:XHG) Bolsa

XChange Tec

XChange Tec Inc, through its subsidiaries operates in insurance agency and insurance technology business. Its insurance products include industry and/or state-owned property and casualty insurance and regional property and casualty insurance. The insurance technology business is focused on operating and developing insurance technology in the PRC, including developing SaaS platform to connect consumers and underwriting support.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AEMD

APCX

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

DALN

DSGN

ELAB

KULR

LITM

MESO

NVNI

PTPI

QNTM

SGMO

SLXN

VRAX

Acciones de Sangamo Therapeutics suben un 19,5% tras un nuevo acuerdo. Descubre los mayores ganadores y perdedores de hoy.

Acciones de Sangamo Therapeutics (SGMO) suben alrededor de un 20%; 20 acciones que se mueven en el premercado

XChange TEC.INC - American Depositary Shares

XChange Tec Inc

IONS

Trading Halt: Halt status updated at 6:55:00 PM ET: Quotation Resumption: News and Resumption Times

Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) hit new yearly highs recently as the overall cryptocurrency sector has traded higher since Donald Trump won the<a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41778425/bitcoins-all-time-high-a-groundbreaking-milestone-and-strong-post-election-rally-coming-ex"> 2024 presidential election.</a>
A new Benzinga poll asks readers if Dogecoin will trade closer to levels seen before the election or all-time highs set back in 2021.
What Happened: Dogecoin traded between 15 cents and 18 cents on Nov. 5, the day of the U.S. presidential election. Like many cryptocurrencies, Dogecoin <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41890024/much-wow-dogecoin-is-now-larger-than-ford-adidas-lululemon-roblox-15-companies-worth-less-than-meme-crypto">gained in the days </a>and weeks after Trump's victory.
Helped by Trump's victory, optimism for a pro-crypto White House administration and the appointment of Dogecoin supporter Elon Musk as head of the Department of Government Efficiency, or D.O.G.E. for short, the meme cryptocurrency hit new <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42274989/dogecoins-insane-165-growth-in-november-is-just-the-first-candle-traders-speculate">yearly highs in November </a>and December.
Benzinga recently asked if the recent momentum in Dogecoin and future optimism would see Dogecoin more likely to trade closer to an all-time high of $0.7376 set in May 2021 or back to the $0.25 level last seen on Nov. 10 shortly after the election.
"Which level is Dogecoin more likely to reach next: 69 cents or 25 cents?" Benzinga asked.
The results were:
<ul>
<li>69 Cents: 78%</li>
<li>25 Cents: 22%</li>
</ul>
The poll found over three-fourths of readers predict Dogecoin is more likely to hit 69 cents before hitting 25 cents again.
This would suggest that Dogecoin has more gains ahead and would set new 52-week highs and get close to all-time highs.
The last time Dogecoin hit 69 cents was on May 9, 2021, the day after the all-time high was set. Dogecoin traded at 69 cents or higher on four occasions in May 2021.
Dogecoin has traded between $0.07497 and $0.4835 over the [ast year, with the high set in early December.
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41908812/if-you-invested-100-in-dogecoin-when-the-meme-coin-launched-heres-how-much-youd-have-today">If You Invested $100 In Dogecoin When The Meme Coin Launched, Here&#8217;s How Much You&#8217;d Have Today</a>
Why It's Important: Recent polls have shown continued optimism for Dogecoin, which is one of the 10 most valuable cryptocurrencies by market capitalization.
A recent <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41945659/dogecoin-to-69-cents-or-1-benzinga-readers-predict-how-high-it-could-fly-by-end-of-2024">November Benzinga poll</a> asked what Dogecoin's highest price by the end of 2024 would be.  
The results were:
<ul>
<li>42 cents: 10%</li>
<li>69 cents: 24%</li>
<li>New All-Time Highs (73.77 cents): 18%</li>
<li>$1.00: 17%</li>
<li>None of the above: 31%</li>
</ul>
The highest percentage of readers thought that none of the price targets would be reached by Dogecoin. The next highest result was 69 cents, which would take Dogecoin close to all-time highs and a memeable number before year-end.
Only 18% of readers think that Dogecoin will reach all-time highs before the end of the year, and a lower percentage (17%) believe Dogecoin will hit a price of $1.
<a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42378513/can-bitcoin-ethereum-dogecoin-shiba-inu-or-solana-beat-xrp-in-2025-poll-says-yes-one-coin-stands-out">A December poll </a>asked if any of the top cryptocurrencies could outperform fast-moving XRP in 2025. The possible answers were Bitcoin, Solana, Dogecoin, Ethereum, Shiba Inu, Hedera or none of the above, meaning XRP would be the top gainer in 2025.
Dogecoin ranked fourth in the poll at 13%, with Bitcoin won the poll at 28%, followed by None of the Above at 24% and Solana at 15%.
DOGE Price Action: Dogecoin trades at $0.3205 at the time of writing, down 11% over the last 24 hours and down 17% over the past month. Despite the recent drop in price, the price of Dogecoin is up over 240% year-to-date in 2024.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42440369/bitcoins-next-move-105000-or-85000-poll-finds-over-60-say">Bitcoin&#8217;s Next Move: $105,000 Or $85,000? Poll Finds Over 60% Say…</a></li>
</ul>
The study was conducted by Benzinga from Dec. 11 through Dec. 12, 2024, and included the responses of a diverse population of adults 18 or older. Opting into the survey was completely voluntary, with no incentives offered to potential respondents. The study reflects results from 123 adults.
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Exclusives

$DOGE

Dogecoin Down 17% In One Month, Will Meme Crypto Reach 25 Cents Or 69 Cents First? 78% Of Readers Say…

Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) has outperformed the market over the past 10 years by 11.19% on an annualized basis producing an average annual return of 22.11%. Currently, Meta Platforms has a market capitalization of $1.51 trillion. 
Buying $1000 In META: If an investor had bought $1000 of META stock 10 years ago, it would be worth $7,388.29 today based on a price of $597.04 for META at the time of writing.
<h3>Meta Platforms's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734651910_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Meta Platforms 10 Years Ago Would Be Worth This Much Today

The debate over how to tackle America's obesity epidemic that affects 40% of adults and nearly<a href="https://www.benzinga.com/general/biotech/24/02/37157967/whats-gaining-popularity-among-us-teens-battling-obesity-novo-nordisks-weight-loss-drug-wegovy" target="_blank" rel="noreferrer noopener">&nbsp;20% of children</a>, has sparked contrasting views from two influential voices in President-elect Donald J. Trump's orbit. The side that wins could have a lasting impact on public health in the U.S.
Robert F. Kennedy Jr., <a href="https://www.benzinga.com/government/regulations/24/11/41993115/trump-taps-rfk-jr-for-health-secretary-role-sends-5-vaccine-stocks-lower">Trump's pick</a> for secretary of Health and Human Services (HHS), says lifestyle changes need to be a big part of the solution.
Elon Musk, billionaire tech entrepreneur and seemingly one of Trump's closest advisers, is calling for easier access to weight loss drugs such as <a href="https://www.benzinga.com/topic/ozempic">Ozempic</a> and <a href="https://www.benzinga.com/topic/wegovy">Wegovy</a>, produced by Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>). Musk, who has used Wegovy, said on X that &#8220;nothing else is even close&#8221; when considering how to address obesity, <a href="https://www.nytimes.com/2024/12/18/health/ozempic-food-rfk-elon-musk.html">noted</a> the New York Times. "Nothing would do more to improve the health, lifespan, and quality of life for Americans than making GLP inhibitors super low cost to the public."
Kennedy, meanwhile, says if approved to lead the HHS, he'll roll out an anti-obesity plan that will focus on healthier nutrition and encouraging Americans to make time for daily exercise. Kennedy told Fox News' Greg Gutfeld before the election that the makers of obesity drugs are &#8220;counting on selling it to Americans because we're so stupid and so addicted to drugs.&#8221;
<h1 class="wp-block-heading">Suicide and Ozempic?</h1>
Kennedy <a href="https://www.youtube.com/watch?v=qX9nQ40mSMY">said in the same Fox News appearance</a> that the European Union "is right now investigating Ozempic for suicidal ideation," although the EU regulator concluded in April that available evidence does not suggest Ozempic and other weight-loss drugs cause suicidal thoughts or actions.
Dr. Michael Osterholm, director of the Center for Infectious Disease Research and Policy at the University of Minnesota says such confident although false or misleading assertions are Kennedy's trademark. And they can be dangerous, Osterholm warned, when applied to public health bedrocks like vaccines.
"He acts like he knows what he's talking about when he doesn't, and he says things with a definition that makes people convinced he has the data to support his statement," Osterholm <a href="https://www.cnn.com/2024/11/17/health/rfk-jr-ozempic/index.html">told</a> CNN two weeks after the November election. "Trying to follow him and understand what he's talking about is often like trying to nail Jell-O to the wall."
Kennedy and Musk's competing perspectives underscore the difficult path toward dealing with the U.S.'s <a href="https://www.benzinga.com/news/24/03/37413349/ozempic-wegovy-other-weight-loss-drugs-wont-solve-global-obesity-crisis-affecting-1b-people-who-warn" target="_blank" rel="noreferrer noopener">severe obesity epidemic</a>: lifestyle changes vs. pharmaceuticals.
<h1 class="wp-block-heading">Cannabis a Solution?</h1>
Some people may look to <a href="https://www.benzinga.com/cannabis">cannabis</a> for a natural solution. Recent studies have <a href="https://www.nature.com/articles/s41366-023-01399-x" target="_blank" rel="noreferrer noopener">suggested</a> &#8220;cannabis and subproducts could be considered adjuncts in obesity treatment by helping to reduce relevant anthropometric measurements.&#8221;
Now Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42491683/rfk-jrs-lawyer-urges-fda-to-revoke-polio-vaccine-approval-endangering-millions-of-children">Kennedy&#8217;s Lawyer Urges FDA To Revoke Polio Vaccine Approval, Endangering Millions Of Children</a></li>
</ul>

Cannabis

Government

Health Care

Politics

Elon Musk Vs. RFK Jr.: Obesity Crisis Debate Sparks Struggle For Trump's Influence

Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) has outperformed the market over the past 20 years by 1.81% on an annualized basis producing an average annual return of 10.01%. Currently, Nike has a market capitalization of $115.16 billion. 
Buying $1000 In NKE: If an investor had bought $1000 of NKE stock 20 years ago, it would be worth $6,789.21 today based on a price of $77.37 for NKE at the time of writing.
<h3>Nike's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734651013_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Nike 20 Years Ago Would Be Worth This Much Today

Chipotle Mexican Grill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) has outperformed the market over the past 15 years by 14.86% on an annualized basis producing an average annual return of 26.48%. Currently, Chipotle Mexican Grill has a market capitalization of $84.14 billion. 
Buying $1000 In CMG: If an investor had bought $1000 of CMG stock 15 years ago, it would be worth $34,170.91 today based on a price of $61.75 for CMG at the time of writing.
<h3>Chipotle Mexican Grill's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734650109_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Chipotle Mexican Grill Stock In The Last 15 Years

Verisk Analytics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSK#NASDAQ">VRSK</a>) has outperformed the market over the past 15 years by 4.07% on an annualized basis producing an average annual return of 15.69%. Currently, Verisk Analytics has a market capitalization of $38.91 billion. 
Buying $100 In VRSK: If an investor had bought $100 of VRSK stock 15 years ago, it would be worth $894.74 today based on a price of $275.58 for VRSK at the time of writing.
<h3>Verisk Analytics's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734649208_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VRSK

If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today

Jones Lang LaSalle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JLL#NYSE">JLL</a>) has outperformed the market over the past 20 years by 1.69% on an annualized basis producing an average annual return of 9.89%. Currently, Jones Lang LaSalle has a market capitalization of $11.72 billion. 
Buying $1000 In JLL: If an investor had bought $1000 of JLL stock 20 years ago, it would be worth $6,666.58 today based on a price of $246.93 for JLL at the time of writing.
<h3>Jones Lang LaSalle's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734648313_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Jones Lang LaSalle 20 Years Ago Would Be Worth This Much Today

BlackBerry Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) reported third-quarter financial results after the market close on Thursday. Here&#8217;s a look at the key metrics <a href="https://www.benzinga.com/pressreleases/24/12/ac42605872/blackberry-reports-third-quarter-fiscal-year-2025-results">from the quarter</a>.
Q3 Earnings: BlackBerry reported third-quarter revenue of $162 million. The company reported third-quarter adjusted earnings of two cents per share, beating analyst <a href="https://www.benzinga.com/calendars/earnings">estimates</a> for a loss of one cent per share, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
IoT revenue was&nbsp;$62&nbsp;million, up 13% year-over-year.&nbsp;Cybersecurity revenue totaled $93&nbsp;million in the quarter, up 7% year-over-year. Licensing revenue&nbsp;came in at $7&nbsp;million.
Total company gross margin was 74% in the quarter. Operating cash flow improved by $34 million year-over-year to $3 million. BlackBerry ended the quarter with $266 million in&nbsp;cash, cash equivalents and&nbsp;short-&nbsp;and long-term investments.
&#8220;BlackBerry achieved a significant inflection in its results this past quarter. Driven by a combination of strong revenue performance for both our Cybersecurity and IoT divisions, and continued focus on costs and efficiency, the company delivered stronger than expected profitability and a return to positive cash flow ahead of schedule,&#8221; said John Giamatteo, CEO of BlackBerry. 
From Last Week: <a href="https://www.benzinga.com/24/12/42477300/russian-state-backed-hackers-target-ukrainian-military-devices-via-spacexs-starlink-microsoft-report-reveals">Russian State-Backed Hackers Target Ukrainian Military Devices Via SpaceX&#8217;s Starlink, Microsoft Reveals</a>
Guidance: BlackBerry expects fourth-quarter revenue of $126 million to $135 million versus estimates of $161.49 million. The company anticipates fourth-quarter IoT revenue of $60 million to $65 million, secure communications revenue of $62 million to $66 million and licensing and other revenue of approximately $4 million.
BlackBerry expects full-year revenue of $517 million to $526 million versus estimates of $603.12 million. The company anticipates full-year adjusted earnings to be somewhere between breakeven and a loss of two cents per share, versus estimates for a loss of two cents per share.
Management will further discuss the quarter on a call with investors and analysts at 5:30 p.m. ET.
BB Price Action:&nbsp;<a href="https://www.benzinga.com/quote/BB" target="_blank" rel="noreferrer noopener">BlackBerry shares</a>&nbsp;were up 0.17% in after hours, trading at $2.98 at the time of publication Thursday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo: Courtesy of BlackBerry.

Earnings

Tech

BlackBerry Beats Q3 Earnings Estimates, But Soft Guidance Keeps Shares In Check

Legal

SVCO

Silvaco Says US Court Of Appeals For The Ninth Circuit Affirmed US District Court's Dismissal Of All Claims Brought By Aldini

ALLETE Says FERC Approved Proposed Transaction With CPP Investments And Global Infrastructure Partners

Guidance

PARR

Par Pacific Expects 2025 Capital Expenditure And Turnaround Outlay Guidance Of $210M - $240M

Marsh &amp; McLennan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) has outperformed the market over the past 10 years by 2.76% on an annualized basis producing an average annual return of 13.69%. Currently, Marsh &amp; McLennan has a market capitalization of $103.31 billion. 
Buying $100 In MMC: If an investor had bought $100 of MMC stock 10 years ago, it would be worth $360.25 today based on a price of $210.35 for MMC at the time of writing.
<h3>Marsh &amp; McLennan's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734647416_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Marsh & McLennan 10 Years Ago Would Be Worth Today

SPRY

ARS Pharmaceuticals Says Express Scripts Has Added neffy (Epinephrine Nasal Spray) To Its Commercial National Formularies

The Stock Repurchase Program will begin on December 19, 2024 and conclude on December 19, 2025.

Buybacks

FRST

Primis Financial Board Approves Stock Repurchase Program For Up To 740,600 Of Outstanding Shares Of Common Stock

As a result of this error, the Bank will record $8.1 million on a pre-tax basis of occupancy expense in the fourth quarter of 2024. On an after-tax basis, this will reduce fourth quarter diluted earnings per share by approximately $0.43.
As for the impact of ASC 842 in future years, it is expected that the correct calculation of lease expense will increase occupancy expense by approximately $1.6 million per year on a pre-tax basis.
It has evaluated the impact to income for each of the periods involved as well as the cumulative impact to 2024's results and have determined the understatement in the prior years as well as the impact to the results for 2024 are not material to the Bank's results of operations or its balance sheet.

PFBC

Preferred Bank Finds Unreconciled Difference In Its Calculation Of Its Right Of Use Asset And Lease Liabilities; Expects Additional Q4 Expense To Reduce Q4 EPS By $0.43

ASAI

Sendas Distribuidora Intends To Proceed With Voluntary Delisting Of Its ADSs From NYSE

BlackBerry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.01) by 300 percent. This is a 100 percent increase over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $143.00 million which missed the analyst consensus estimate of $150.76 million by 5.15 percent. This is a 18.29 percent decrease over sales of $175.00 million the same period last year.

BlackBerry Q3 2025 Sales $143.00M Miss $150.76M Estimate

FCPT

Four Corners Property Trust Reports Acquisition Of A MercyOne Outpatient Clinic Property For $2.8M

BlackBerry is providing the following guidance for the fourth quarter and the full fiscal year 2025 (ending February 28, 2025).&nbsp;
As the sale of the Company's Cylance business is expected to close during the fourth quarter of 2024, that business is reported this quarter as discontinued operations, and the following guidance, except for non-GAAP basic EPS, is reflective solely of the expected results of the Company's continuing operations.

BlackBerry Now Expects FY25 Total Revenue Of $517M - $526M (Est $603.12M), Non-GAAP Basic EPS Of $(0.02) - Breakeven (Est $(0.02))

XChange TECINC (XHG) has released an update. XChange TEC.INC has announced a change in the ratio of its American depositary shares (ADSs), which ef...

XChange TEC.INC Announces ADS Ratio Change

XChange TEC.INC (XHG)announced that it plans to change the ratio of the American depositary shares representing its Class A ordinary shares from on...

XChange TEC.INC  plans to implement ADS ratio change

XChange TEC announces plan to implement ADS ratio change

19:50 EST XChange TEC.INC (XHG)(ADR) trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving brea...

XChange TEC.INC (ADR) trading halted, news pending

XChange TEC.INC (XHG)announced that it has received a notice from The Nasdaq Stock Market LLC dated November 8, 2024 stating that the company is no...

XChange TEC.INC  receives Nasdaq bid price deficiency notice

XChange TEC.INC receives Nasdaq deficiency notice

XChange TECINC (XHG) has released an update. XChange TEC.INC has received a notice from Nasdaq indicating non-compliance with the $1 minimum bid pr...

XChange TEC.INC Faces Nasdaq Listing Challenge

XChange TEC.INC (XHG)announced that it has received a notice from The Nasdaq Stock Market LLC dated November 13, 2024 stating that the company is n...

XChange TECINC (XHG) has released an update. XChange TEC.INC has successfully regained compliance with Nasdaq's listing requirements, ensuring its ...

XChange TEC.INC Regains Nasdaq Compliance

XChange TEC.INC (XHG)announced that it has received a notice from The Nasdaq Stock Market dated November 26 stating that the company has regained c...

XChange TEC.INC  regains Nasdaq compliance

Insurance

Press Releases

XChange TEC.INC Announces Receipt of Positive Decision by Nasdaq Hearings Panel and Approval of Transfer of Listing to The Nasdaq Capital Market

XChange TEC.INC Announces Receipt of Nasdaq Notification of Regaining Listing Compliance

Fintech

XChange TEC.INC Announces Entry into $25.0 Million Committed Equity Facility with VG Master Fund SPC

XChange TEC.INC Announces Plan to Implement ADS Ratio Change

XChange TEC.INC RECEIVES NASDAQ MINIMUM BID PRICE DEFICIENCY NOTICE

XChange TEC.INC RECEIVES NASDAQ MINIMUM MARKET VALUE DEFICIENCY NOTICE

XChange TEC.INC RECEIVES NASDAQ NOTICE OF REGAINING COMPLIANCE

Abacus Life

Arthur J. Gallagher

Aon plc Class A Ordinary Shares (Ireland)

Brown & Brown

The Baldwin Insurance Group, Inc. - Class A Common Stock

Baldwin Insurance

Cheche Group Inc. - Class A Ordinary Shares

Cheche Group

Crawford & Company Common Stock

eHealth

GoHealth

Goosehead Insurance, Inc. - Class A Common Stock

Goosehead Insurance

Hagerty

Hippo Holdings

Huize Holding Limited - American Depositary Shares

Huize Holding

Marsh & McLennan Companies, Inc. Common Stock

Marsh & McLennan

Ryan Specialty Holdings, Inc. Class A Common Stock

Ryan Specialty Hldgs

SelectQuote

TIAN RUIXIANG Holdings Ltd - Class A Ordinary Shares

Tian Ruixiang Holdings

TWFG

Waterdrop Inc. American Depositary Shares (each representing the right to receive 10 Class A Ordinary Shares)

Comments

XChange Tec

Noticias

Últimas noticias sobre XChange Tec (NASDAQ:XHG) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL